Lupin Q2 preview: New launches and approvals to likely aid 37% growth in profit

Lupin-the country's leading pharma major is slated to report its Q2 earnings later today. Zee Business research estimates the company to report decent performance with consolidated net profit seen to zoom 37 per cent on-year to Rs 670 crore. In the same period last year, the company's profit was recorded at Rs 490 crore.

Revenue from operations at the company are expected to climb 9 per cent year-on-year (YoY) to Rs 5,479 crore as against Rs 5,038 crore reported during the same period a-year ago.

Analysts forecasts a  better and improved performance during the September quarter on the back of new launches as well as approvals.

Operationally, the company's EBITDA or Earnings Before Interest, Taxes, Depreciation, and Amortization is seen jumping 25 per cent YoY to Rs 1,149 crore, from Rs 918 crore reported in the same quarter of the previous year.

EBITDA margins are also expected to report significant increase of 3 per cent or 300 basis points to 21 per cent from 18 per cent reported in the same period of the previous year.

Analysts expect US sales to be around US$229 million during the quarter under review, whiile the domestic formulations segment is anticipated to grow by 11 per cent during the period.

Key monitorables

Stakeholders will watch out for approvals in the niche products category.
 
Lupin's share price performance

Ahead of its results later today, shares of the company traded weak by 0.8 per cent at Rs 2,148 per share on the BSE. The stock in the last one year has zoomed 79 per cent and is now trading with a gain of over 86 per cent from its 52-week low price.